Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

Sarfaraz K. Niazi, PhD, dives into the role that biosimilar associations and organizations play in promoting biosimilars as ...

When compared with reference aflibercept, a biosimilar ranibizumab was a clinically effective and cost-saving alternative in ...

Number 5: The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the ...